AC Immune SA
https://www.acimmune.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AC Immune SA
Anti-Tau For Alzheimer's In The Dock After Semorinemab Fail
Hopes that the Phase II TAURIEL trial could potentially validate the anti-tau antibody approach to treating Alzheimer's have been dashed as semorinemab did not meet its endpoints.
Finance Watch: One Small Pain Drug Maker And Three Biotech SPACs Launch IPOs
After a brief lull in US initial public offerings, PainReform and three special purpose acquisition companies kicked off September’s IPOs. Also, Immunovant offering grossed $173.9m, Carlyle Group bought 5% stake in China’s Salubris and Erasca increased its series B to $236m.
Roche Partners With UCB On Anti-Tau Alzheimer’s Drug
UCB gets $120m up front from Roche for option rights to UCB0107 and retains full rights to the drug in progressive supranuclear palsy.
Lilly May Face Q2 Blues As Prior Stocking Takes Effect
Changing payer mix in diabetes due to the impacts of COVID-19 may be a central focus of Lilly's second quarter earnings call.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Drug Discovery Tools
- Large Molecule
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Molecular Diversity
- Other Names / Subsidiaries
-
- AC Immune, Ltd.